RECURSION PHARMACEUTICALS-A (RXRX) Stock Price & Overview
NASDAQ:RXRX • US75629V1044
The current stock price of RXRX is 3.29 USD. Today RXRX is down by -4.64%. In the past month the price decreased by -11.32%. In the past year, price decreased by -48.19%.
RXRX Key Statistics
- Market Cap
- 1.735B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.48
- Dividend Yield
- N/A
RXRX Stock Performance
RXRX Stock Chart
RXRX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to RXRX. When comparing the yearly performance of all stocks, RXRX is a bad performer in the overall market: 90.9% of all stocks are doing better.
RXRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RXRX. While RXRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
RXRX Earnings
On February 25, 2026 RXRX reported an EPS of -0.21 and a revenue of 35.54M. The company beat EPS expectations (34.79% surprise) and beat revenue expectations (41.71% surprise).
RXRX Forecast & Estimates
14 analysts have analysed RXRX and the average price target is 7.14 USD. This implies a price increase of 117.02% is expected in the next year compared to the current price of 3.29.
For the next year, analysts expect an EPS growth of 33.75% and a revenue growth 38.52% for RXRX
RXRX Groups
Sector & Classification
RXRX Financial Highlights
Over the last trailing twelve months RXRX reported a non-GAAP Earnings per Share(EPS) of -1.48. The EPS increased by 10.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.74% | ||
| ROE | -57.01% | ||
| Debt/Equity | 0.01 |
RXRX Ownership
RXRX Latest News, Press Relases and Analysis
RXRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 402.577B | ||
| AMGN | AMGEN INC | 16.11 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.5 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RXRX
Company Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 600 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Company Info
IPO: 2021-04-16
RECURSION PHARMACEUTICALS-A
41S Rio Grande Street
Salt Lake City UTAH 84101 US
CEO: Christopher Gibson
Employees: 600
Phone: 13026744089
RECURSION PHARMACEUTICALS-A / RXRX FAQ
What does RECURSION PHARMACEUTICALS-A do?
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 600 full-time employees. The company went IPO on 2021-04-16. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The firm integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
What is the current price of RXRX stock?
The current stock price of RXRX is 3.29 USD. The price decreased by -4.64% in the last trading session.
What is the dividend status of RECURSION PHARMACEUTICALS-A?
RXRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of RXRX stock?
RXRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy RXRX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RXRX.
What is the market capitalization of RXRX stock?
RECURSION PHARMACEUTICALS-A (RXRX) has a market capitalization of 1.74B USD. This makes RXRX a Small Cap stock.
Who owns RECURSION PHARMACEUTICALS-A?
You can find the ownership structure of RECURSION PHARMACEUTICALS-A (RXRX) on the Ownership tab.